In this episode of Sounds of Science, learn how the Retrogenix® platform is reshaping drug development by identifying off-target risks earlier, reducing animal use, and gaining traction with regulators—now as part of the FDA’s ISTAND pilot program. Guests Nick Brown and Mark Aspinall-O’Dea from Charles River Discovery Services share real-world insights on their role in advancing NAMs and supporting safer, faster therapeutic development.

Show Notes 

• Maximize Safer, Targeted Biologic Development with Smarter NAMs-Based Off-Target Screening 
• Paving the Way for Enhanced Drug Development 
• A Status Report on Cell-Based Protein Arrays 
• Retrogenix® Human Protein Library 
• Retrogenix®: The Screen Door of Drug Development 
• Retrogenix® CAR Specificity Testing 
• Charles River Launched New Retrogenix Non-Human Protein Library